Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Single-arm Phase 3B Implementation Study to Evaluate the Effectiveness of the Homologous Boost of Ad26.COV2.S COVID-19 Vaccine Following the Prime Dose Among Sisonke Participants in South Africa(VAC31518COV30XX)

NCT05148845 is registered in ClinicalTrials.gov with Wits Health Consortium (Pty) Ltd as lead sponsor.

NCT NCT05148845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05148845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Single-arm Phase 3B Implementation Study to Evaluate the Effectiveness of the Homologous Boost of Ad26.COV2.S COVID-19 Vaccine Following the Prime Dose Among Sisonke Participants in South Africa(VAC31518COV30XX)
Lead sponsor
Wits Health Consortium (Pty) Ltd
Phase
Phase 3
Overall status
Completed
Start date
November 10, 2021
Completion date
June 30, 2023
Enrollment
500,000 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

sars cov 2 infection